An interventional study of Screening for FH in Heterozygous Familial Hypercholesterolemia (HeFH), Homozygous Familial Hypercholesterolemia (HoFH) and Familial Hypercholesterolemia, sponsored by University of Wisconsin, Madison. Recruiting at 1 site in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-10-13.
Sponsored by University of Wisconsin, Madison · Not applicable, Interventional, and Diagnostic
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 36 studies in Homozygous Familial Hypercholesterolemia with a site in United States — 7 open to participants now, 9 under way, 4 of them phase 3. Homozygous Familial Hypercholesterolemia · United States.
Among the 36 studies in Homozygous Familial Hypercholesterolemia with a site in United States, this one is the 8th largest by planned enrollment of the 31 interventional ones that give a count, is one of 2 that started in 2026, is one of 3 with no phase, and was the 34th registered.
68 studies on the registry are indexed under Homozygous Familial Hypercholesterolemia; 13 are open to participants now.
Browse Homozygous Familial Hypercholesterolemia studies →7 of the 36 studies in Homozygous Familial Hypercholesterolemia with a site in United States are open now. Recruiting first, the newest first:
Arrowhead Pharmaceuticals · Sites in United States, Denmark, Poland
Ages 12–17
Novartis Pharmaceuticals · Sites in United States, Austria, China and 8 more countries
Ages 2–11
CRISPR Therapeutics AG · Sites in United States, Australia, New Zealand and 1 more country
Ages 18–75
Novartis Pharmaceuticals · Sites in United States, Argentina, Brazil and 23 more countries
Ages 2–100
University of Pennsylvania · Sites in United States, Netherlands, South Africa
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 12 Homozygous Familial Hypercholesterolemia studies recruiting now, 6 (50%) set no upper age limit and 5 (42%) stop at 75 or younger; 8 take children under 18; none take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
36 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 2 · Phase 2 11 · Phase 3 18
First in 2003; this study’s year is marked. 2 started in 2026.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 70 is above the median of 21 across 51 interventional studies indexed under Homozygous Familial Hypercholesterolemia.
Median enrollment 29 across the 31 interventional studies, 60 across the 5 observational. Of the 26 that completed or were terminated, 19 (73%) have results posted.
This tab as a report to print or save as PDF → With an account.
32 of 36 have an industry lead sponsor. The 10 most frequent:
University of Wisconsin, Madison is the lead sponsor of 1,190 studies on the registry; 181 are open to participants now.
Of its 157 completed or terminated interventional studies of FDA-regulated products, 118 (75%) have results posted.
University of Wisconsin, Madison has 1 study filed under Homozygous Familial Hypercholesterolemia — fewer than ten, so there is no comparison to draw.
3 of the studies in Homozygous Familial Hypercholesterolemia with a site in United States that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07037771Phase 3Arrowhead PharmaceuticalsA Phase 3 Study of Zodasiran in Adolescent and Adult Subjects With Homozygous Familial Hypercholesterolemia (YOSEMITE) | 2027-08-20 |
| NCT04815005University of PennsylvaniaHoFH, the International Clinical Collaborators Registry | 2026-12-31 |
| NCT07491172CRISPR Therapeutics AGA Safety and Tolerability Trial Evaluating CTX310 in Participants With Refractory Dyslipidemias | 2027-06 |
Add all 3 to your calendar (.ics) → With an account.
Among the 36 studies in Homozygous Familial Hypercholesterolemia with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The goal of this clinical trial is to identify different types of Familial Hypercholesterolemia (FH) in infants and newborns. Participants will:
Participants can expect to be in the trial for 2 years.
ORIGIN-FH is a two-phase cohort study that will identify and enroll expectant parents where one or both partners has phenotypic and/or genotypic familial hypercholesterolemia in order to prospectively screen and diagnose their newborns with HoFH, HeFH, or are unaffected by FH.
The criteria were revised on the registry on Oct 13, 2026. See what changed
Inclusion Criteria - parent participant:
Inclusion Criteria - newborn participant:
Exclusion Criteria - parent and newborn participants:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Newborns screened for FH
Diagnostic Test: Screening for FH
Participants will provide 5 blood samples for screening for FH.
Number of diagnostically confirmed HoFH newborns born to expectant parent partnerships where one or both partners have phenotypic HoFH or HeFH.
Time frame: 2 years
Number of diagnostically confirmed HeFH newborns born to expectant parent partnerships where one or both partners have phenotypic HoFH or HeFH.
Time frame: 2 years
Differences in Low Density Lipoprotein Cholesterol (LDL-C)
LDL-C will be measured and compared between newborns with HeFH/HoFH and those not affected by FH.
Time frame: 1 month, 2 years
Differences in Total Cholesterol (TC)
TC will be measured and compared between newborns with HeFH/HoFH and those not affected by FH.
Time frame: 1 month, 2 years
Differences in Apolipoprotein B (apoB)
ApoB will be measured and compared between newborns with HeFH/HoFH and those not affected by FH.
Time frame: 1 month, 2 years
Differences in Lipoprotein A (Lp(a))
Lp(a) will be measured and compared between newborns with HeFH/HoFH and those not affected by FH.
Time frame: 1 month, 2 years
Plan to share: Yes
No publications or documents are linked to this record.
Started Feb 2026 (actual). Primary completion is estimated for Feb 2029, 36 months after the start.
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Homozygous Familial Hypercholesterolemia →
University of Wisconsin, Madison →